Share-based Payment Arrangement, Expense of ZEVRA THERAPEUTICS, INC. from 31 Dec 2013 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
ZEVRA THERAPEUTICS, INC. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2013 to 31 Dec 2025.
  • ZEVRA THERAPEUTICS, INC. Share-based Payment Arrangement, Expense for the quarter ending 31 Dec 2025 was $4,284,000, a 6.6% increase year-over-year.
  • ZEVRA THERAPEUTICS, INC. Share-based Payment Arrangement, Expense for the twelve months ending 31 Dec 2025 was $12,634,000, a 15% decline year-over-year.
  • ZEVRA THERAPEUTICS, INC. annual Share-based Payment Arrangement, Expense for 2025 was $12,634,000, a 15% decline from 2024.
  • ZEVRA THERAPEUTICS, INC. annual Share-based Payment Arrangement, Expense for 2024 was $14,906,000, a 150% increase from 2023.
  • ZEVRA THERAPEUTICS, INC. annual Share-based Payment Arrangement, Expense for 2023 was $5,954,000, a 39% increase from 2022.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

ZEVRA THERAPEUTICS, INC. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $12,634,000 $4,284,000 +$266,000 +6.6% 01 Oct 2025 31 Dec 2025 10-K 09 Mar 2026 2025 FY
Q3 2025 $12,368,000 $2,771,000 -$3,366,000 -55% 01 Jul 2025 30 Sep 2025 10-Q 05 Nov 2025 2025 Q3
Q2 2025 $15,734,000 $2,464,000 -$168,000 -6.4% 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $15,902,000 $3,115,000 +$996,000 +47% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $14,906,000 $4,018,000 +$1,145,000 +40% 01 Oct 2024 31 Dec 2024 10-K 09 Mar 2026 2025 FY
Q3 2024 $13,761,000 $6,137,000 +$4,750,000 +342% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2025 2025 Q3
Q2 2024 $9,011,000 $2,632,000 +$1,529,000 +139% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025 2025 Q2
Q1 2024 $7,482,000 $2,119,000 +$1,528,000 +259% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q4 2023 $5,954,000 $2,873,000 +$1,918,000 +201% 01 Oct 2023 31 Dec 2023 10-K 12 Mar 2025 2024 FY
Q3 2023 $4,036,000 $1,387,000 +$476,000 +52% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024 2024 Q3
Q2 2023 $3,560,000 $1,103,000 -$407,000 -27% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024 2024 Q2
Q1 2023 $3,967,000 $591,000 -$327,000 -36% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $4,294,000 $955,000 +$132,000 +16% 01 Oct 2022 31 Dec 2022 10-K 01 Apr 2024 2023 FY
Q3 2022 $4,162,000 $911,000 +$291,000 +47% 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 $3,871,000 $1,510,000 +$1,192,000 +375% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 $2,679,000 $918,000 +$243,000 +36% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q4 2021 $2,436,000 $823,000 +$366,000 +80% 01 Oct 2021 31 Dec 2021 10-K 07 Mar 2023 2022 FY
Q3 2021 $2,070,000 $620,000 +$235,000 +61% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $1,835,000 $318,000 -$302,000 -49% 01 Apr 2021 30 Jun 2021 10-Q 12 Aug 2022 2022 Q2
Q1 2021 $2,137,000 $675,000 -$354,000 -34% 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q4 2020 $2,491,000 $457,000 -$289,000 -39% 01 Oct 2020 31 Dec 2020 10-K 31 Mar 2022 2021 FY
Q3 2020 $2,780,000 $385,000 -$672,000 -64% 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $3,452,000 $620,000 -$697,000 -53% 01 Apr 2020 30 Jun 2020 10-Q 13 Aug 2021 2021 Q2
Q1 2020 $4,149,000 $1,029,000 -$261,000 -20% 01 Jan 2020 31 Mar 2020 10-Q 14 May 2021 2021 Q1
Q4 2019 $4,410,000 $746,000 -$502,000 -40% 01 Oct 2019 31 Dec 2019 10-K 12 Mar 2021 2020 FY
Q3 2019 $4,912,000 $1,057,000 -$1,529,000 -59% 01 Jul 2019 30 Sep 2019 10-Q 30 Oct 2020 2020 Q3
Q2 2019 $6,441,000 $1,317,000 -$63,000 -4.6% 01 Apr 2019 30 Jun 2019 10-Q 12 Aug 2020 2020 Q2
Q1 2019 $6,504,000 $1,290,000 +$9,000 +0.7% 01 Jan 2019 31 Mar 2019 10-Q 13 May 2020 2020 Q1
Q4 2018 $6,495,000 $1,248,000 +$98,000 +8.5% 01 Oct 2018 31 Dec 2018 10-K 28 Feb 2020 2019 FY
Q3 2018 $6,397,000 $2,586,000 +$1,428,000 +123% 01 Jul 2018 30 Sep 2018 10-Q 14 Nov 2019 2019 Q3
Q2 2018 $4,969,000 $1,380,000 +$215,000 +18% 01 Apr 2018 30 Jun 2018 10-Q 13 Aug 2019 2019 Q2
Q1 2018 $4,754,000 $1,281,000 +$192,000 +18% 01 Jan 2018 31 Mar 2018 10-Q 14 May 2019 2019 Q1
Q4 2017 $4,562,000 $1,150,000 +$108,000 +10% 01 Oct 2017 31 Dec 2017 10-K 01 Mar 2019 2018 FY
Q3 2017 $4,454,000 $1,158,000 -$2,121,000 -65% 01 Jul 2017 30 Sep 2017 10-Q 09 Nov 2018 2018 Q3
Q2 2017 $6,575,000 $1,165,000 -$92,000 -7.3% 01 Apr 2017 30 Jun 2017 10-Q 10 Aug 2018 2018 Q2
Q1 2017 $6,667,000 $1,089,000 +$67,000 +6.6% 01 Jan 2017 31 Mar 2017 10-Q 11 May 2018 2018 Q1
Q4 2016 $6,600,000 $1,042,000 +$129,000 +14% 01 Oct 2016 31 Dec 2016 10-K 30 Mar 2018 2017 FY
Q3 2016 $6,471,000 $3,279,000 +$2,787,000 +566% 01 Jul 2016 30 Sep 2016 10-Q 09 Nov 2017 2017 Q3
Q2 2016 $3,684,000 $1,257,000 +$384,000 +44% 01 Apr 2016 30 Jun 2016 10-Q 10 Aug 2017 2017 Q2
Q1 2016 $3,300,000 $1,022,000 +$931,000 +1023% 01 Jan 2016 31 Mar 2016 10-Q 22 May 2017 2017 Q1
Q4 2015 $2,369,000 $913,000 +$869,000 +1975% 01 Oct 2015 31 Dec 2015 10-K 30 Mar 2018 2017 FY
Q3 2015 $1,500,000 $492,000 +$440,000 +846% 01 Jul 2015 30 Sep 2015 10-Q 10 Nov 2016 2016 Q3
Q2 2015 $1,060,000 $873,000 +$781,000 +849% 01 Apr 2015 30 Jun 2015 10-Q 11 Aug 2016 2016 Q2
Q1 2015 $279,000 $91,000 +$65,000 +250% 01 Jan 2015 31 Mar 2015 10-Q 13 May 2016 2016 Q1
Q4 2014 $214,000 $44,000 01 Oct 2014 31 Dec 2014 10-K 10 Mar 2017 2016 FY
Q3 2014 $52,000 01 Jul 2014 30 Sep 2014 10-Q 13 Nov 2015 2015 Q3
Q2 2014 $92,000 01 Apr 2014 30 Jun 2014 10-Q 14 Aug 2015 2015 Q2
Q1 2014 $26,000 01 Jan 2014 31 Mar 2014 10-Q 29 May 2015 2015 Q1

ZEVRA THERAPEUTICS, INC. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $12,634,000 -$2,272,000 -15% 01 Jan 2025 31 Dec 2025 10-K 09 Mar 2026 2025 FY
2024 $14,906,000 +$8,952,000 +150% 01 Jan 2024 31 Dec 2024 10-K 09 Mar 2026 2025 FY
2023 $5,954,000 +$1,660,000 +39% 01 Jan 2023 31 Dec 2023 10-K 12 Mar 2025 2024 FY
2022 $4,294,000 +$1,858,000 +76% 01 Jan 2022 31 Dec 2022 10-K 01 Apr 2024 2023 FY
2021 $2,436,000 -$55,000 -2.2% 01 Jan 2021 31 Dec 2021 10-K 07 Mar 2023 2022 FY
2020 $2,491,000 -$1,919,000 -44% 01 Jan 2020 31 Dec 2020 10-K 31 Mar 2022 2021 FY
2019 $4,410,000 -$2,085,000 -32% 01 Jan 2019 31 Dec 2019 10-K 12 Mar 2021 2020 FY
2018 $6,495,000 +$1,933,000 +42% 01 Jan 2018 31 Dec 2018 10-K 28 Feb 2020 2019 FY
2017 $4,562,000 -$2,038,000 -31% 01 Jan 2017 31 Dec 2017 10-K 01 Mar 2019 2018 FY
2016 $6,600,000 +$4,231,000 +179% 01 Jan 2016 31 Dec 2016 10-K 30 Mar 2018 2017 FY
2015 $2,369,000 +$2,155,000 +1007% 01 Jan 2015 31 Dec 2015 10-K 30 Mar 2018 2017 FY
2014 $214,000 +$80,000 +60% 01 Jan 2014 31 Dec 2014 10-K 10 Mar 2017 2016 FY
2013 $134,000 01 Jan 2013 31 Dec 2013 10-K 16 Mar 2016 2015 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.